title: Cytogenetic assessment of heterogeneous radiation doses in cancer patients treated with fractionated radiotherapy.
abstract: The purpose of this study was to evaluate the in vivo dose-response relation of chromosome aberration formation and distribution in a context of localised and fractionated radiotherapy. Cytogenetic analysis was applied to eight patients, all treated for the same tumour localisation; the same localisation was used to prevent the variability usually observed between patients treated with radiotherapy and to allow the corresponding roles of the size of irradiation field and of the dose rate to be studied. The yield of dicentrics, centric rings and fragments was measured in blood samples taken before treatment, during the course of radiotherapy and up to 6 months after. After the first fraction of radiotherapy, we observed that the whole-body dose estimated from the yield of dicentrics and rings was higher (0.35+/-0.2 Gy) than the calculated equivalent whole-body dose (0.07+/-0.04 Gy). By contrast, the partial-body dose derived from the Qdr (quotient of dicentrics and rings) model was estimated to be 2.2+/-0.3 Gy, which agreed quite well with the dose delivered to the tumour (2.1+/-0.1 Gy). We also found a correlation between the yield of induced chromosome aberrations and the target field size (p = 0.014). U-value analysis showed that the distribution of dicentrics and rings was overdispersed, despite the fractionation of the exposure, and a positive correlation between the U-value and the dose rate was observed (p = 0.017). Overall, these results suggest that the proportion of undamaged lymphocytes could increase with the dose rate.
authors.affiliation: DRPH/SRBE/LDB, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France. sandrine.roch-lefevre@irsn.fr
authors.forename: S
authors.initials: S
authors.lastname: Roch-Lefèvre
authors.forename: F
authors.initials: F
authors.lastname: Pouzoulet
authors.forename: A L
authors.initials: AL
authors.lastname: Giraudet
authors.forename: Pa
authors.initials: P
authors.lastname: Voisin
authors.forename: A
authors.initials: A
authors.lastname: Vaurijoux
authors.forename: G
authors.initials: G
authors.lastname: Gruel
authors.forename: E
authors.initials: E
authors.lastname: Grégoire
authors.forename: V
authors.initials: V
authors.lastname: Buard
authors.forename: M
authors.initials: M
authors.lastname: Delbos
authors.forename: Ph
authors.initials: P
authors.lastname: Voisin
authors.forename: J
authors.initials: J
authors.lastname: Bourhis
authors.forename: L
authors.initials: L
authors.lastname: Roy
mesh_terms: D000368:Aged; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis / Q000379:methods; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000532:radiotherapy*; D006801:Humans; D008214:Lymphocytes / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged